Cardiff Oncology (CRDF) Receivables (2011 - 2026)
Cardiff Oncology (CRDF) posted Receivables of $482000.0 for Q4 2025, up 89.76% sequentially from $254000.0 in Q3 2025, and down 58.91% YoY from $1.2 million in Q4 2024.
Cardiff Oncology (CRDF) Receivables (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported Receivables for 15 years, with the latest figure at $482000.0 in Q4 2025.
- Quarterly Receivables fell 58.91% year-over-year to $482000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $482000.0 (down 58.91% YoY) and the FY2025 annual result came in at $482000.0, down 58.91% from the prior year.
- Receivables improved to $482000.0 in Q4 2025 per CRDF's latest filing, from $254000.0 in the prior quarter.
- Over five years, Receivables peaked at $1.3 million in Q4 2022 and troughed at $161000.0 in Q2 2023.
- A 5-year average of $531200.0 and a median of $466500.0 in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2024: Receivables plunged 70.78% in 2023, then jumped 212.12% in 2024.
- Over 5 years, Receivables stood at $535000.0 in 2021, then soared by 137.57% to $1.3 million in 2022, then plunged by 30.13% to $888000.0 in 2023, then jumped by 32.09% to $1.2 million in 2024, then plunged by 58.91% to $482000.0 in 2025.
- According to Business Quant data, Receivables over the past three periods registered $482000.0, $254000.0, and $526000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | 189,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189,000.00 |
| Dec 31, 2025 | 482,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Jun 30, 2025 | 526,000.00 |
| Mar 31, 2025 | 405,000.00 |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 618,000.00 |
| Jun 30, 2024 | 451,000.00 |
| Mar 31, 2024 | 393,000.00 |
| Dec 31, 2023 | 888,000.00 |
| Sep 30, 2023 | 198,000.00 |
| Jun 30, 2023 | 161,000.00 |
| Mar 31, 2023 | 676,000.00 |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 650,000.00 |
| Jun 30, 2022 | 551,000.00 |
| Mar 31, 2022 | 447,000.00 |
| Dec 31, 2021 | 535,000.00 |
| Sep 30, 2021 | 395,000.00 |
| Jun 30, 2021 | 308,000.00 |